Lipoprotein(a) Reductions From PCSK9 Inhibition and Major Adverse Cardiovascular Events: Pooled Analysis of Alirocumab Phase 3 Trials
Atherosclerosis - Netherlands
doi 10.1016/j.atherosclerosis.2019.06.896
Full Text
Open PDFAbstract
Available in full text
Date
September 1, 2019
Authors
Publisher
Elsevier BV